Big Box Expansion And Soft Chew Capacity Will Transform Long Term Pet Health Prospects

Catalysts

About Swedencare

Swedencare develops and sells pet health products and provides contract development and manufacturing services to animal health companies.

What are the underlying business or industry changes driving this perspective?

• Expansion into major U.S. Big Box and pharmacy chains such as over 2,000 Walmart stores and CVS, together with dedicated in store displays and incremental marketing, increases shelf space and brand visibility for NaturVet, which can support higher long term revenue from the U.S. pet retail channel.
• Growing online penetration in pet products, with Swedencare highlighting online as its strongest North American channel and high subscription rates in dental, points to a larger recurring revenue base and improved earnings quality as digital sales scale.
• Global rollout of Vetio soft chew technology across three manufacturing sites in North America and Europe, combined with strong customer interest in soft chews in both pharma and supplements, positions Swedencare to capture more formulation work and volume, which can support revenue growth and operating margins.
• Investment in sterile fill and finish capacity in Montreal, backed by an anchor client and described as addressing an unmet need in animal health, expands Swedencare's addressable CMO market into injectables and potentially vaccines, which can increase higher value development and manufacturing revenue and support EBITDA.
• Rising focus on pet wellness categories such as dental care, supplements and treats, together with product extensions like dental wipes, cat focused dental launches and pill pastes, gives Swedencare more ways to cross sell through vets, retail and online, which can support revenue per customer and group earnings.

Assumptions

This narrative explores a more optimistic perspective on Swedencare compared to the consensus, based on a Fair Value that aligns with the bullish cohort of analysts. How have these above catalysts been quantified?

• The bullish analysts are assuming Swedencare's revenue will grow by 10.6% annually over the next 3 years.
• The bullish analysts assume that profit margins will increase from 2.4% today to 10.6% in 3 years time.
• The bullish analysts expect earnings to reach SEK 382.2 million (and earnings per share of SEK 2.41) by about February 2029, up from SEK 62.9 million today. The analysts are largely in agreement about this estimate.
• In order for the above numbers to justify the price target of the more bullish analyst cohort, the company would need to trade at a PE ratio of 27.2x on those 2029 earnings, down from 58.1x today. This future PE is lower than the current PE for the SE Pharmaceuticals industry at 55.1x.
• The bullish analysts expect the number of shares outstanding to grow by 0.62% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 5.07%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• Reliance on Big Box and major online channels like Walmart, CVS, PetSmart and Amazon increases exposure to retailer bargaining power, inventory reductions and promotional demands. This can pressure pricing, require higher marketing spend and weigh on gross margin and operating earnings if these partners tighten terms or reduce orders over time.
• Veterinary channel softness in North America, with flat vet visits and cautious inventory management by large vet customers, points to a structural risk that pet owners rely less on vets for purchases. This could limit growth in higher value veterinary products and services and constrain revenue and operating margins in the production and vet focused lines.
• Ongoing expansion of manufacturing capacity, including sterile fill and finish in Montreal and the planned Jupiter, Florida campus, requires meaningful upfront investment and depends on anchor clients and project pipelines. Any slowdown in outsourced pharma demand or delays in filling capacity could leave Swedencare with underutilised assets, pressuring EBITDA margins and cash generation.
• The business is increasingly tied to online sales and Amazon fees, with Amazon related external costs already rising. Changes in platform algorithms, fee structures or competitive intensity could raise customer acquisition and distribution costs and reduce the profitability of online channels, weighing on net margins and earnings growth.
• Acquisition led growth and international expansion, including Summit, Pack Approved, VetWorthy and Viyo, raise integration and execution risk. If acquired units underperform or synergies do not materialise, Swedencare may face higher net debt relative to EBITDA, weaker cash conversion and pressure on group earnings.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The assumed bullish price target for Swedencare is SEK55.0, which represents up to two standard deviations above the consensus price target of SEK47.5. This valuation is based on what can be assumed as the expectations of Swedencare's future earnings growth, profit margins and other risk factors from analysts on the bullish end of the spectrum.
  
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of SEK55.0, and the most bearish reporting a price target of just SEK40.0.
  
• In order for you to agree with the more bullish analyst cohort, you'd need to believe that by 2029, revenues will be SEK3.6 billion, earnings will come to SEK382.2 million, and it would be trading on a PE ratio of 27.2x, assuming you use a discount rate of 5.1%.
  
• Given the current share price of SEK22.85, the analyst price target of SEK55.0 is 58.5% higher.
  
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.